MicroRNA-944 overexpression is a biomarker for poor prognosis of advanced cervical cancer

Sunyoung Park, Jungho Kim, Kiyoon Eom, Sehee Oh, Sunghyun Kim, Geehyuk Kim, Sungwoo Ahn, Kwang Hwa Park, Dawn Chung, Hyeyoung Lee

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: One-third of cervical cancer patients are still diagnosed at advanced stages. The five-year survival rate is decreased in about 50% of advanced stage cervical cancer patients worldwide, and the clinical outcomes are remarkably varied and difficult to predict. One of the miRNAs known to be associated with cancer tumorigenesis is miR-944. However, the prognostic value of miR-944 in cervical cancer has not been fully investigated. The aim of this study was to analyze clinical significance and prognostic value of miR-944 in cervical cancer. Methods: The expression levels of miR-944 were detected using quantitative reverse transcription polymerase chain reaction in five types of cervical cancer cell lines and 116 formalin-fixed paraffin-embedded (FFPE) cervical tissues. The association between the expression levels of miR-944 and prognostic value was analyzed using the Kaplan-Meier analysis and Cox proportional hazards model. Results: The expression levels of miR-944 in cervical cancer tissues were significantly higher compared with those in normal tissues (P < 0.0001). Moreover, the expression levels of miR-944 in cervical cancer cell lines and FFPE tissues with human papillomavirus (HPV) infection were significantly higher compared to those without HPV infection (P < 0.01 and P = 0.02). High miR-944 expression was also markedly associated with bulky tumor size (P = 0.026), advanced International Federation of Gynecology and Obstetrics (FIGO) stage (P = 0.042), and lymph node metastasis (P = 0.030). In particular, high miR-944 expression group showed shorter overall survival than the low miR-944 expression group in the advanced FIGO stage (84.4% vs. 44.4%, HR = 4.0, and P = 0.01). Conclusions: These results suggest that miR-944 may be used as a novel biomarker for improving prognosis and as a potential therapeutic target.

Original languageEnglish
Article number419
JournalBMC cancer
Volume19
Issue number1
DOIs
Publication statusPublished - 2019 May 6

Fingerprint

MicroRNAs
Uterine Cervical Neoplasms
Biomarkers
Papillomavirus Infections
Gynecology
Paraffin
Formaldehyde
Obstetrics
Cell Line
Kaplan-Meier Estimate
Proportional Hazards Models
Reverse Transcription
Neoplasms
Carcinogenesis
Survival Rate
Lymph Nodes
Neoplasm Metastasis
Polymerase Chain Reaction
Survival

All Science Journal Classification (ASJC) codes

  • Genetics
  • Oncology
  • Cancer Research

Cite this

Park, Sunyoung ; Kim, Jungho ; Eom, Kiyoon ; Oh, Sehee ; Kim, Sunghyun ; Kim, Geehyuk ; Ahn, Sungwoo ; Park, Kwang Hwa ; Chung, Dawn ; Lee, Hyeyoung. / MicroRNA-944 overexpression is a biomarker for poor prognosis of advanced cervical cancer. In: BMC cancer. 2019 ; Vol. 19, No. 1.
@article{fcb73f00474247b680ba241d3918caf2,
title = "MicroRNA-944 overexpression is a biomarker for poor prognosis of advanced cervical cancer",
abstract = "Background: One-third of cervical cancer patients are still diagnosed at advanced stages. The five-year survival rate is decreased in about 50{\%} of advanced stage cervical cancer patients worldwide, and the clinical outcomes are remarkably varied and difficult to predict. One of the miRNAs known to be associated with cancer tumorigenesis is miR-944. However, the prognostic value of miR-944 in cervical cancer has not been fully investigated. The aim of this study was to analyze clinical significance and prognostic value of miR-944 in cervical cancer. Methods: The expression levels of miR-944 were detected using quantitative reverse transcription polymerase chain reaction in five types of cervical cancer cell lines and 116 formalin-fixed paraffin-embedded (FFPE) cervical tissues. The association between the expression levels of miR-944 and prognostic value was analyzed using the Kaplan-Meier analysis and Cox proportional hazards model. Results: The expression levels of miR-944 in cervical cancer tissues were significantly higher compared with those in normal tissues (P < 0.0001). Moreover, the expression levels of miR-944 in cervical cancer cell lines and FFPE tissues with human papillomavirus (HPV) infection were significantly higher compared to those without HPV infection (P < 0.01 and P = 0.02). High miR-944 expression was also markedly associated with bulky tumor size (P = 0.026), advanced International Federation of Gynecology and Obstetrics (FIGO) stage (P = 0.042), and lymph node metastasis (P = 0.030). In particular, high miR-944 expression group showed shorter overall survival than the low miR-944 expression group in the advanced FIGO stage (84.4{\%} vs. 44.4{\%}, HR = 4.0, and P = 0.01). Conclusions: These results suggest that miR-944 may be used as a novel biomarker for improving prognosis and as a potential therapeutic target.",
author = "Sunyoung Park and Jungho Kim and Kiyoon Eom and Sehee Oh and Sunghyun Kim and Geehyuk Kim and Sungwoo Ahn and Park, {Kwang Hwa} and Dawn Chung and Hyeyoung Lee",
year = "2019",
month = "5",
day = "6",
doi = "10.1186/s12885-019-5620-6",
language = "English",
volume = "19",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",
number = "1",

}

Park, S, Kim, J, Eom, K, Oh, S, Kim, S, Kim, G, Ahn, S, Park, KH, Chung, D & Lee, H 2019, 'MicroRNA-944 overexpression is a biomarker for poor prognosis of advanced cervical cancer', BMC cancer, vol. 19, no. 1, 419. https://doi.org/10.1186/s12885-019-5620-6

MicroRNA-944 overexpression is a biomarker for poor prognosis of advanced cervical cancer. / Park, Sunyoung; Kim, Jungho; Eom, Kiyoon; Oh, Sehee; Kim, Sunghyun; Kim, Geehyuk; Ahn, Sungwoo; Park, Kwang Hwa; Chung, Dawn; Lee, Hyeyoung.

In: BMC cancer, Vol. 19, No. 1, 419, 06.05.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - MicroRNA-944 overexpression is a biomarker for poor prognosis of advanced cervical cancer

AU - Park, Sunyoung

AU - Kim, Jungho

AU - Eom, Kiyoon

AU - Oh, Sehee

AU - Kim, Sunghyun

AU - Kim, Geehyuk

AU - Ahn, Sungwoo

AU - Park, Kwang Hwa

AU - Chung, Dawn

AU - Lee, Hyeyoung

PY - 2019/5/6

Y1 - 2019/5/6

N2 - Background: One-third of cervical cancer patients are still diagnosed at advanced stages. The five-year survival rate is decreased in about 50% of advanced stage cervical cancer patients worldwide, and the clinical outcomes are remarkably varied and difficult to predict. One of the miRNAs known to be associated with cancer tumorigenesis is miR-944. However, the prognostic value of miR-944 in cervical cancer has not been fully investigated. The aim of this study was to analyze clinical significance and prognostic value of miR-944 in cervical cancer. Methods: The expression levels of miR-944 were detected using quantitative reverse transcription polymerase chain reaction in five types of cervical cancer cell lines and 116 formalin-fixed paraffin-embedded (FFPE) cervical tissues. The association between the expression levels of miR-944 and prognostic value was analyzed using the Kaplan-Meier analysis and Cox proportional hazards model. Results: The expression levels of miR-944 in cervical cancer tissues were significantly higher compared with those in normal tissues (P < 0.0001). Moreover, the expression levels of miR-944 in cervical cancer cell lines and FFPE tissues with human papillomavirus (HPV) infection were significantly higher compared to those without HPV infection (P < 0.01 and P = 0.02). High miR-944 expression was also markedly associated with bulky tumor size (P = 0.026), advanced International Federation of Gynecology and Obstetrics (FIGO) stage (P = 0.042), and lymph node metastasis (P = 0.030). In particular, high miR-944 expression group showed shorter overall survival than the low miR-944 expression group in the advanced FIGO stage (84.4% vs. 44.4%, HR = 4.0, and P = 0.01). Conclusions: These results suggest that miR-944 may be used as a novel biomarker for improving prognosis and as a potential therapeutic target.

AB - Background: One-third of cervical cancer patients are still diagnosed at advanced stages. The five-year survival rate is decreased in about 50% of advanced stage cervical cancer patients worldwide, and the clinical outcomes are remarkably varied and difficult to predict. One of the miRNAs known to be associated with cancer tumorigenesis is miR-944. However, the prognostic value of miR-944 in cervical cancer has not been fully investigated. The aim of this study was to analyze clinical significance and prognostic value of miR-944 in cervical cancer. Methods: The expression levels of miR-944 were detected using quantitative reverse transcription polymerase chain reaction in five types of cervical cancer cell lines and 116 formalin-fixed paraffin-embedded (FFPE) cervical tissues. The association between the expression levels of miR-944 and prognostic value was analyzed using the Kaplan-Meier analysis and Cox proportional hazards model. Results: The expression levels of miR-944 in cervical cancer tissues were significantly higher compared with those in normal tissues (P < 0.0001). Moreover, the expression levels of miR-944 in cervical cancer cell lines and FFPE tissues with human papillomavirus (HPV) infection were significantly higher compared to those without HPV infection (P < 0.01 and P = 0.02). High miR-944 expression was also markedly associated with bulky tumor size (P = 0.026), advanced International Federation of Gynecology and Obstetrics (FIGO) stage (P = 0.042), and lymph node metastasis (P = 0.030). In particular, high miR-944 expression group showed shorter overall survival than the low miR-944 expression group in the advanced FIGO stage (84.4% vs. 44.4%, HR = 4.0, and P = 0.01). Conclusions: These results suggest that miR-944 may be used as a novel biomarker for improving prognosis and as a potential therapeutic target.

UR - http://www.scopus.com/inward/record.url?scp=85065650488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065650488&partnerID=8YFLogxK

U2 - 10.1186/s12885-019-5620-6

DO - 10.1186/s12885-019-5620-6

M3 - Article

C2 - 31060525

AN - SCOPUS:85065650488

VL - 19

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

IS - 1

M1 - 419

ER -